Stockwinners Market Radar for June 21, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:32 EDT Terns Pharmaceuticals to highlight data supporting TERN-501 - Terns Pharmaceuticals announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association 84th Scientific Sessions, taking place June 21-24, 2024 in Orlando, FL. The presentation reports results from a preclinical study in mice fed a high fat diet for 24 weeks prior to study start. Obese mice were treated once daily with vehicle, TERN-501, semaglutide, TERN-501+semaglutide, or tirzepatide for six weeks. The combination of TERN-501+ semaglutide significantly enhanced weight loss compared to semaglutide alone. Additionally, the TERN-501+semaglutide combination showed proportionally greater loss of fat mass relative to lean mass compared to semaglutide alone, indicating improved quality of weight loss. The study also explored metabolic adaptation, a counter regulatory process that decreases energy expenditure and limits the magnitude and sustainability of weight loss. Mice treated with semaglutide and tirzepatide showed significant weight loss that was associated with decreases in energy expenditure. When TERN-501 was combined with semaglutide, weight loss-induced lowering of energy expenditure was prevented and increases in the thermogenesis marker, UCP-1, were observed in subcutaneous adipose tissue. TERN-501 has potential to attenuate metabolic adaptation and normalize energy expenditure, which may enhance the weight loss efficacy of GLP-1 therapies.

18:22 EDT NJOY receives first FDA authorizations for menthol e-vapor products - Altria Group announces that the U.S. FDA issued marketing orders for NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod Menthol 5%, NJOY DAILY Menthol 4.5%, and NJOY DAILY Extra Menthol 6%. These authorizations follow FDA review of the Premarket Tobacco Product Applications, submitted by NJOY, LLC in March 2020. NJOY ACE remains the only pod-based e-vapor product with marketing authorization from the FDA, and now NJOY has the first and only menthol e-vapor products authorized by the FDA to date. "Altria is Moving Beyond Smoking(TM), taking action to transition millions of adult smokers to potentially less harmful alternatives. We're pleased the FDA has determined that NJOY menthol e-vapor products are appropriate for the protection of public health," said Billy Gifford, Altria's CEO. In the first quarter of 2024, NJOY broadened distribution to over 80,000 stores and expects to expand to approximately 100,000 stores by year-end. NJOY also continued the roll-out of the brand's first retail trade program, which is designed to help achieve optimal retail visibility and product fixture space.

16:59 EDT Penske Automotive says many of CDK's systems remain inoperable - In a regulatory filing, Penske Automotive stated, "On June 19, 2024, we became aware that CDK Global, LLC, a provider of dealer management software systems to retail automotive and commercial truck dealerships, was experiencing a cybersecurity incident and its systems were not operational. As of the filing of this Current Report, many of CDK's systems remain inoperable. We do not utilize CDK's dealer management system in our U.S. or international automotive dealership operations. Our Premier Truck Group business utilizes CDK's dealer management system which has been disrupted. We immediately took precautionary containment steps to protect our systems and commenced an investigation of the incident, which efforts are ongoing. Premier Truck Group has implemented its business continuity response plans and continues to operate at all locations through manual or alternate processes developed to respond to such incidents. The commercial truck dealership business has lower unit volumes than the automotive dealership business and principally serves business customers."

16:31 EDT NeuroSense receives delisting notice from Nasdaq, plans to appeal - NeuroSense Therapeutics announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the company's securities have not regained compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(b). The Notice further states that unless the company timely requests a hearing before a Nasdaq Hearings Panel, the company's securities would be subject to delisting. Accordingly, the company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing. Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the company an additional extension not to exceed December 18, 2024. At the hearing, the company will present its plan for regaining and sustaining compliance with the Equity Requirement for continued listing.

16:20 EDT Safehold announces $750M commercial paper note program - Safehold announced that its operating company, Safehold GL Holdings, has established an unsecured commercial paper note program in the United States. Under the terms of the program, the operating company may issue from time to time unsecured commercial paper notes up to a maximum aggregate amount outstanding at any one time of $750M. The notes will be sold under customary terms in the United States commercial paper note market and will rank pari passu with all of the operating company's other unsecured senior indebtedness. The notes will be fully and unconditionally guaranteed by the company. Note proceeds will be used for general corporate purposes. The company expects to realize cost of capital benefits in the commercial paper market versus its $2B revolving credit facility, and expects to use its revolving credit facility as a liquidity backstop for the repayment of the notes issued under the commercial paper program.

16:17 EDT Sonic Automotive: CDK suspended certain systems after cyber incident - In a regulatory filing, Sonic Automotive disclosed that on June 19, a third-party provider of certain information systems used by Sonic Automotive notified its dealership customers that CDK had suspended certain systems, including systems used by the company, in response to a cybersecurity incident impacting CDK. As a result, the company experienced disruptions to its dealer management system hosted by CDK, which supports critical dealership operations including those supporting sales, inventory and accounting functions and its customer relationship management system. All of the company's dealerships are open and operating utilizing workaround solutions to minimize the disruption caused by this CDK outage. Upon detection of the unauthorized activity, the company immediately took precautionary containment steps to protect the company's systems and commenced an investigation of the incident. As the incident is ongoing, the full scope, nature and impact of the incident, including the extent to which the threat actor accessed any customer data, are not yet known. While this incident has had, and is likely to continue to have, a negative impact on the company's business operations until the relevant systems are fully restored, the company has not yet determined whether the incident is reasonably likely to have a material impact on the company's financial condition or results of operations.

16:01 EDT Takeda receives approval from European Commission for FRUZAQLA - Takeda announced that the European Commission approved FRUZAQLA as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2024, and approval by the U.S. FDA for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.

20:00 EDT ResMed shares slip after Eli Lilly reports sleep apnea study data - ResMed shares are down $9.37, or 4%, to $203.90 in late Friday trading.

15:52 EDT FitLife Brands Inc trading halted, volatility trading pause

14:26 EDT Redwoods Acquisition Corp trading resumes

18:30 EDT FDA approves Mirati's Krazati sNDA for colorectal cancer - The FDA has approved Mirati Therapeutics' Krazati in combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, or CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, according to an amended label posted to the agency's website. On January 23, Bristol Myers Squibb (BMY) announced that it had successfully completed its acquisition of Mirati Therapeutics. Reference Link

13:01 EDT Baker Hughes reports U.S. rig count down 2 to 588 rigs

12:04 EDT Asana rises 9.0% - Asana is up 9.0%, or $1.02 to $12.39.

12:03 EDT Li-Cycle rises 13.5% - Li-Cycle is up 13.5%, or 62c to $5.21.

12:02 EDT Trex Company falls -7.4% - Trex Company is down -7.4%, or -$6.24 to $77.78.

12:00 EDT Jumia Technologies falls -9.1% - Jumia Technologies is down -9.1%, or -72c to $7.19.

11:24 EDT Fibrobiologics Inc trading resumes

11:14 EDT Fibrobiologics Inc trading halted, volatility trading pause

15:06 EDT FDA authorizes marketing of four menthol-flavored e-cigarette products - The Food and Drug Administration announced it authorized the marketing of four e-cigarette products in the United States through the premarket tobacco product application, or PMTA, pathway. The FDA issued marketing granted orders to NJOY LLC for four menthol-flavored e-cigarette products - NJOY ACE Pod Menthol 2.4%, NJOY ACE Pod Menthol 5%, NJOY DAILY Menthol 4.5%, and NJOY DAILY EXTRA Menthol 6%. The two authorized ACE products are sealed, pre-filled, non-refillable pods that are used with the previously authorized ACE device, and the two authorized DAILY products are disposable e-cigarettes with a prefilled, non-refillable e-liquid reservoir. "Today's authorizations mark the first non-tobacco flavored e-cigarette products to be authorized by the FDA. Importantly, each application is reviewed on a case-by-case basis and today's actions are specific to these four products only - the authorizations do not apply to any other menthol-flavored e-cigarette products," the FDA stated. Publicly traded companies in the tobacco products space include Altria Group (MO), British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM).

10:20 EDT Kartoon Studios, Inc trading resumes

10:10 EDT NASB Financial announces $25B stock repurchase program - NASB Financial announced that its Board of Directors has authorized a new stock repurchase program of up to $25M of the company's outstanding common stock. The new stock repurchase program will terminate on June 1, 2027, unless earlier terminated by the Board of Directors.

10:05 EDT Ryan Specialty rises 6.6% - Ryan Specialty is up 6.6%, or $3.68 to $59.04.

14:04 EDT Kartoon Studios to launch 'Winnie-The-Pooh' brand on Amazon Prime Video - Kartoon Studios (TOON) announced Kartoon Studios' "Winnie-the-Pooh" project. Plans include an animated holiday movie, five holiday specials, and a four year/104 episode series, to premiere on Amazon Prime Video (AMZN), via Kartoon Channel!'s subscription service on the platform. Concurrently, Alliance Entertainment (AENT) will debut new merchandise through a nationwide retail program, in conjunction with Kartoon Studios rollout of a global consumer products campaign. Pre-production has already begun on the animated holiday movie, set to premiere December 24, 2025, on Amazon Prime Video, through Kartoon Channel!'s $3.99/month subscription distribution agreement with them. Concurrently, the global retail program will kick off with the debut of products featuring an array of special features, distributed through Alliance Entertainment Corporation.

10:02 EDT On Holding falls -7.4% - On Holding is down -7.4%, or -$3.08 to $38.65.

10:00 EDT a.k.a. Brands falls -11.5% - a.k.a. Brands is down -11.5%, or -$1.68 to $12.86.

09:51 EDT Spirit AeroSystems rises 5.9% - Spirit AeroSystems is up 5.9%, or $1.87 to $33.53.

09:49 EDT Studio City rises 8.0% - Studio City is up 8.0%, or 50c to $6.75.

09:48 EDT On Holding falls -7.6% - On Holding is down -7.6%, or -$3.17 to $38.56.

09:47 EDT a.k.a. Brands falls -11.9% - a.k.a. Brands is down -11.9%, or -$1.73 to $12.81.

09:40 EDT EHang secures order for 30 units of EH216-S, plan for additional 270 units - EHang Holdings has signed a cooperation agreement with the government of Wencheng County, Wenzhou City, Zhejiang Province, to jointly develop UAM and supporting public service ecosystem for the low-altitude economy. Based on this cooperation, Wencheng County Transportation Development Group Co., Ltd. has signed a purchase agreement with EHang for 30 units of the EH216-S and has already paid 50% of the total contract price as a pre-delivery down payment, with the remainder payable upon delivery. Additionally, the customer plans to purchase an additional 270 units of EH216-S by the end of 2026 and already paid a non-refundable deposit. Looking ahead, EHang and Wencheng County will work together in establishing a low-altitude industry chain across the region, including demonstration, sales, maintenance, and operations of pilotless passenger-carrying aerial vehicle, to create momentum and advantages that drives the development of economy and UAM ecosystem within Zhejiang Province. Wencheng County, a top ten ecological tourism city in Zhejiang Province, is a typical demonstration county for low-altitude economy application scenarios in the southeastern coastal mountainous areas. With its rich natural resources, low-altitude economy application in Wencheng hold great potential. Wencheng County will join EHang to spearhead the development of aerial tourism and explore innovative commercial applications. This collaboration aims to provide thrilling aerial sightseeing experiences for visitors, utilizing the county's wealth of scenic natural attractions.

09:37 EDT Feutune Light Acquisition Corp trading halted, volatility trading pause

09:30 EDT Orchestra Biomed Holdings Inc trading halted, volatility trading pause

09:11 EDT Sharecare trading halted, news pending

09:07 EDT Wrap Technologies CEO says company 'laser-focused' on execution - CEO Scot Cohen said, in part, "We are at a pivotal time in Wrap Technologies and I'm excited to share with you that we believe that we're emerging stronger than ever. First, as you are all aware we are actively addressing both our audit and Nasdaq compliance issues. New Auditors: Thirty days ago, we engaged HTL as our new auditors. They are progressing through our 2023 audit, and we do not anticipate any need for restatement of our financials. NASDAQ Compliance: On June 17, 2024, we submitted a comprehensive compliance plan to the NASDAQ Listing Qualifications Department. While there is no guarantee of acceptance, we are hopeful that NASDAQ will grant us sufficient time to complete our 10-K for 2023 and the 10-Q for the first quarter ended March 31, 2024. Today's company looks very different than it did at the end of 2023 when we pursued an aggressive growth strategy and expanded manufacturing operations in preparation for anticipated international demand. Our recent audit provided a valuable opportunity to holistically reassess our business operations, leading to the implementation of heightened discipline, structure, and controls. It became apparent that we were clearly on the wrong path and our recent auditing endeavors provided us with crucial insights, prompting a strategic pivot. First, we have achieved a significant reduction in our operational expenses, decreasing from as high as $2.5 million per month in 2022 to an anticipated $700,000 per month by the end of 2024. This would represent a 72% reduction in our operating expense model. These profound changes establish a more sustainable structure, including tough decisions regarding workforce adjustments. These measures, in conjunction with our accounts receivable, should furnish us with the necessary runway to seize upcoming market opportunities. Second, through closer engagement with our customers and pilot deployments in major cities, it has become evident that Wrap's solutions are not merely non-lethal devices but vital de-escalation solutions. Moreover, Wrap is well positioned to become a preeminent provider of de-escalation solutions, both domestically and internationally. We are committed to deepening our investments in customer success and product delivery with our considerable existing inventory. Along the way, we intend to capture essential use of force data to aid our clients in successfully implementing de-escalation strategies. Our planned solutions are expected to be purpose-built and designed to integrate operationally into law enforcement agencies and packaged for elected officials as they answer the public safety needs of their constituents. Finally, we are laser-focused on execution. We are refining our leadership and simplifying organizational structures to enhance focus, agility, and speed in decision-making...Assuming leadership six months ago, I did so with a firm belief in our purpose to transform public safety through the widespread adoption of our de-escalation tools, technologies, and training. The changes we are implementing across our organization are designed to refine our focus on what sets Wrap Technologies apart from the competition, positioning us to emerge as a stronger, more impactful company."

09:04 EDT Riverview Bancorp appoints Nicole Sherman as president, CEO - Riverview Bancorp announced that Nicole Sherman has been named President and CEO of Riverview Bancorp and Riverview Bank, effective July 01, 2024. She also will join the Boards of Directors of both the Company and the Bank. Sherman brings over 25 years of experience at the Chief, Executive and Senior VP levels with organizations such as Columbia Bank, Utah First, Numerica Credit Union, AmericanWest Bank, and Zions Bank. Over the past nine months, Dan Cox has served as the bank's acting CEO/President. Dan will now focus full-time on his role as EVP, COO.

13:03 EDT Squarespace to sell Tock platform to American Express for $400M - Squarespace (SQSP) announced an agreement to sell Tock, the reservation, table, and event management technology provider, to American Express (AXP) for $400M. As part of the deal, Squarespace and American Express will also partner to deliver additional value for small businesses that use American Express Cards through the Amex Offers program and Card Member benefits. The transaction is subject to customary closing conditions, including regulatory approval.

09:02 EDT Coca-Cola Consolidated announces final results of tender offer - Coca-Cola Consolidated announced the final results of its modified "Dutch auction" tender offer, which expired at 5:00 p.m., New York City time, on June 18, 2024. Based on the final count by Equiniti Trust Company, LLC, the depositary for the tender offer, a total of 14,391.5 shares of the Company's Common Stock were validly tendered and not validly withdrawn in the tender offer. In accordance with the terms and conditions of the tender offer, the Company has accepted for purchase 14,391.5 shares of its Common Stock at a price of $925 per share, for an aggregate cost of approximately $13.3 million, excluding fees and expenses relating to the tender offer. The Company accepted for purchase all of the shares that were validly tendered and not validly withdrawn in the tender offer. The shares accepted for purchase represent approximately 0.2% of the shares of Common Stock that were issued and outstanding as of June 18, 2024.

13:01 EDT TEN, Ltd. announces results of annual general meeting - TEN, Ltd. announced today that the Company's General Annual Meeting of Shareholders was duly held in Athens on June 14, 2024 pursuant to a Notice of Annual Meeting of Shareholders dated May 3, 2024. At the meeting which was conducted with a quorum of its common shares represented in person or by proxy, all of the resolutions proposed were approved by at least 89,27% or higher of the votes cast.

08:32 EDT Lead Real Estate announces voluntary lock-up restrictions for management - Lead Real Estate announces that on May 8, 2024, Chairman and CEO Eiji Nagahara, CFO, Daisuke Takahashi, and a director of the Company voluntarily entered into lock-up agreements for the benefit of the Company. The Lock-up Agreements cover approximately 12 million LRE shares they collectively own, representing about 90% of the outstanding shares of the Company. The Lock-up Agreements will remain in effect until November 7, 2024.

08:30 EDT Cerus announces symposium, abstracts as ISBT - Cerus Corporation announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion, ISBT, taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress.

08:19 EDT Crown Electrokinetics announces 1-for-150 reverse stock split - Crown Electrokinetics expects to implement a 1-for-150 reverse stock split on its common stock with trading to begin on a split-adjusted basis at the market open on Tuesday, June 25, 2024. Trading in the common stock will continue on the Nasdaq Capital Market under the symbol "CRKN". The new CUSIP number for the common stock following the reverse stock split is 228339404. The reverse stock split at a ratio of 1-for-150 shares was approved by the Company's Board of Directors on June 12, 2024, subject to stockholder approval, and the Company's stockholders at the Annual Meeting which was held on June 14, 2024.

12:16 EDT Unusual Machines selected to provide drone for Red Cat's FANG line - Unusual Machines (UMAC) will provide the first drone and components in Red Cat's (RCAT) new FANG line of First-Person View systems. This partnership underscores Unusual Machines' commitment to onshoring drone and component production, as well as its expertise in FPV technology. Red Cat recently introduced its new family of low-cost, portable unmanned Intelligence, Surveillance, and Reconnaissance and precision strike systems.

08:11 EDT Kartoon Studios, Inc trading halted, news pending

08:10 EDT Super League CEO sees 'record revenues' in 2024 - CEO Ann Hand said, in part, "As we approach the halfway mark of the year, I wanted to provide a business update around some of the positive momentum we've continued to generate. Super League's size and duration of programs continue to grow across all verticals with both new and existing customers. This is evidenced by the six seven-figure deals we've closed year to date including Visa and Toyota. To put this into perspective, last year we closed six seven-figure deals in total. In terms of duration, this year we already have seven branded programs that have recurring operational revenue attached to the experience with brands including Dave & Busters and Claire's. We continue to gain traction with major retail brands such as Skechers where we created the first immersive Skechers store within Roblox's Livetopia Topia Mall. The results were compelling with 3.4 million visits to the store, 4 million try-ons, and nearly 45 million impressions generated in just the first five weeks alone. We were also instrumental in the development of a unique experience combining music, art, and technology for a live Post Malone concert at the Louvre in Roblox. Given the nascent industry we are in, the more traction we gain with our brand partners through the one-of-a-kind experiences we create, the more we innovate and enhance. For example, following our Kraft Lunchables program, we launched our white label rewards module which offers in-game player badges and rewards driving the digital to physical conversion. Repeatable elements of our custom experiences enable this conversion across brands and key verticals which led us to launch Super League Pop-ups. These are "drag and drop" modules that can be easily reskinned for use by a wide berth of brands and IP owners. They are currently available through our suite of software tools that help developers improve user engagement with more than 7,000 experiences signed up to date reaching 130+ million monthly active users. This not only lowers the barrier to entry for brands looking to engage these massive immersive worlds, but also accelerates the development phase and presents a compelling margin profile. We drive real engagement that leads to real commerce. The opportunity in front of us remains enticing with strong secular industry tailwinds driving growth in these lucrative 3D worlds where an impressive 500 million people play, shop and socialize. As we grow, we're finding powerful new applications for digital experiential campaigns in areas such as cost-efficient research and development at scale with real-time feedback for test products, or even human resources where our products and technology can deliver results that redefine the traditional office interaction. As we look ahead, we expect our growing pipeline and operational efficiencies to drive record revenues in 2024 with growth consistent with our historical trajectory, leading to profitability in the second half of the year, which ultimately, should drive significant shareholder value."

08:08 EDT Super Hi appoints Yang Lijuan as CEO - Super Hi International announced the appointment of Yang Lijuan as the new CEO and as executive director of the Company, effective July 1, 2024. Yang has served in a number of roles at Haidilao International, including as a director from July 2015 to January 2018, as the COO from January 2018 to March 2022, as the deputy CEO from August 2021 to March 2022, as an executive director from August 2021 to June 2024, and as the CEO from March 2022 to June 2024. Yang's appointment follows the resignation of Mr. Li Yu as CEO of Super Hi, effective July 1, 2024. Mr. Li will continue to serve the Company as a senior regional manager and as an executive director, helping to ensure his successor's smooth transition into her new role. In addition, Mr. Wang Jinping has resigned as executive director and COO of Super Hi, effective July 1, 2024, to focus on new business incubation for the Company. Following the foregoing changes, the Company's board of directors will consist of four directors, namely Ms. Shu Ping, Ms. Yang Lijuan, Mr. Li Yu, Ms. Liu Li and three independent directors, namely Mr. Tan Kang Uei, Mr. Teo Ser Luck, and Mr. Lien Jown Jing, effective July 1, 2024.

08:05 EDT Iterum announces FDA advisory committee meeting for oral sulopenem NDA - Iterum Therapeutics announced that the U.S. Food and Drug Administration has determined that the New Drug Application for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in adult women will be taken to Advisory Committee, and in its communication, highlighted that the purpose of the Advisory Committee was to discuss antimicrobial stewardship issues raised by potential approval and subsequent use of what would be the first oral penem in the U.S.; and the most appropriate target patient population for treatment of uUTI with sulopenem etzadroxil/probenecid. The proposed date for the Advisory Committee meeting is September 9, 2024. In April 2024, the Company announced that it had resubmitted its NDA to the FDA for oral sulopenem for the treatment of uUTIs in adult women. In May 2024, the FDA acknowledged receipt of the resubmission of the NDA. Under the Prescription Drug User Fee Act, the FDA deemed the Company's NDA resubmission to be a Class II complete response which has a six-month review period from the date of resubmission. As a result, the FDA has assigned a PDUFA action date of October 25, 2024.

08:03 EDT IntercontinentalExchange announces IBA to launch USD SOFR ICE Swap Rate - Intercontinental Exchange announced that ICE Benchmark Administration Limited, IBA, intends to launch USD SOFR ICE Swap Rate Swap Spreads and EUR EUR STR ICE Swap Rates for use as benchmarks in financial contracts and financial instruments by licensees on July 1, 2024. "Following successful testing, we are pleased to announce a further expansion of IBA's suite of ICE Swap Rate benchmarks to include SOFR swap spreads and EUR STR swap rates," said Clive de Ruig, President of IBA. "IBA continues to innovate and develop its regulated benchmark offering to ensure that we can provide reliable and relevant benchmark data to our customers."

08:01 EDT WNS Holdings appoints Chintapallis as EO, Head of Strategic Growth - WNS Limited announced that Anil Chintapalli has joined the company as an Executive Officer, EO, and Head of Strategic Growth Initiatives. Anil will report to Group CEO, Keshav Murugesh, and help drive key company-wide growth initiatives including large deals, existing client relationships, geographic markets, and M&A.

07:33 EDT Shimmick CFO Devin Nordhagen to step down, Amanda Mobley named interim - Shimmick Corporation announced organizational changes in its finance leadership to further deliver on its transformation into a more selective and focused water infrastructure company. Amanda Mobley will become interim CFO, replacing Devin Nordhagen, who is stepping down from his position as CFO to pursue other business interests. Mr. Nordhagen will remain with the Company for a period of time to assist with an orderly transition. Mobley has been with Shimmick and its predecessors since 2011 in a variety of financial management roles including being responsible for project accounting and financial reporting.

07:30 EDT Johnson & Johnson completes acquisition of Proteologix for $850M in cash - Johnson & Johnson announced that it has successfully completed the acquisition of Proteologix, a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024. "We look forward to continuing the development of PX-128 and PX-130 alongside the Proteologix team as they join Johnson & Johnson," said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine. "These two bispecific antibodies have the potential to become best in disease therapeutics for people living with moderate to severe atopic dermatitis and asthma by targeting multiple disease-driving pathways. We are thrilled to start integrating them into our industry leading Immunology portfolio."

07:19 EDT Clene presents preliminary data on CNM-Au8 in Rett Syndrome - Clene presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome. Karen Ho, Ph.D., Clene's vice president of translational medicine, unveiled the data in oral and poster presentations on June 19th at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado. The presentation was titled, "CNM-Au8, a Candidate First-in-Class Nanotherapeutic for Treatment of Rett Syndrome." Rett Syndrome is a severe, rare pediatric neurologic disorder caused by mutations in the X chromosome-linked gene, methyl-CpG binding protein 2. The disorder primarily affects females, with an incidence of ~1:10,000 live female births. Children with mutations in MECP2 develop normally until about 6 months of age, after which they exhibit a regression in acquired skills and begin to display a wide range of neurological and developmental impairments that include hand-wringing with loss of purposeful hand movement, abnormal gait, respiratory dysregulation, autism spectrum features, motor dysfunction, loss of verbal communication skills, seizures, and Parkinson-like features. Microcephaly and white matter loss are pathological features of the Rett brain. There is currently only one approved drug for the treatment of Rett Syndrome, trofinetide, which was approved by the U.S. Food and Drug Administration in 2023. CNM-Au8 is an orally administered, catalytic nanotherapeutic that targets energy metabolism via mitochondria in nervous system cells, including neurons and oligodendrocytes, to enhance neuronal survival and function as well as to support remyelination. To date, Clene has focused on the development of CNM-Au8 for the treatment of ALS and MS. The novel mechanism of CNM-Au8, with its catalytic ability to bolster mitochondrial function to aid in the survival and function of neurons, as well as the remyelinating properties of CNM-Au8, led Clene to also consider Rett Syndrome as a possible indication for treatment by CNM-Au8. The project was conducted in collaboration with Dr. Kathrin Meyer, formerly of Nationwide Children's Hospital in Columbus, Ohio, now Chief Scientific Officer of Alcyone Therapeutics, and her former postdoctoral researchers, Drs. Meysam Ganjibakhsh and Andrea Sierra Delgado. Dr. Delgado was former Chief Research Associate in the Meyer lab and is now Research Assistant Professor at the University of Missouri. The study's main preliminary findings are: Statistically significant improvement in neuronal health, neuron survival, and neurite lengthsin an in vitro model of Rett Syndrome, and; Improvements in the mitochondrial respiration deficits associated with Rett patient-derived astrocytes with CNM-Au8 treatment in vitro, with full rescue of both basal and ATP-linked respiration observed in one Rett line, and partial rescue observed in a second Rett line at one concentration of CNM-Au8 treatment for 24 hours. All statistical analyses were done using one-way ANOVA, and all conditions were performed with a minimum of three replicates.

07:16 EDT Village Farms reminds shareholders to cast annual meeting votes - Village Farms International reminds shareholders to exercise their voting rights for the Company's upcoming annual meeting, which will be held virtually on Friday, June 28, 2024 at 12:00 p.m. Eastern time.

07:12 EDT Applied Optoelectronics, Molex settle patent infringement dispute - Applied Optoelectronics has settled its patent infringement dispute and related litigation against Molex, LLC on mutually satisfactory terms. Details regarding the confidential settlement agreement were not disclosed.

07:03 EDT Ocugen says DSMB approves high dose cohort dosing in OCU410ST study - Ocugen announced that the Data and Safety Monitoring Board for the OCU410ST GARDian clinical trial recently convened and approved to proceed with dosing the high dose of OCU410ST in the dose-escalation phase of the study. OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the U.S. and Europe combined. Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date in the low dose cohort and medium dose cohort. An additional three patients will be dosed with the high dose in cohort 3. The Phase 1/2 GARDian clinical trial will include up to 42 subjects-30 adults and 12 children with Stargardt disease-who exhibit mild to moderate disease symptoms and will assess the safety of unilateral subretinal administration of OCU410ST. The clinical trial is being conducted in two phases. Phase 1 is a multicenter, open-label, dose-ranging/dose-escalation study consisting of three dose levels. Phase 2 is a randomized, outcome accessor-blinded, dose-expansion study in which adult and pediatric subjects will be enrolled in a 1:1:1 ratio to randomize subjects into two different treatment groups at varying dose levels, or a control, allowing for a comprehensive assessment of the treatment's efficacy across different dosages. Currently, patients with Stargardt disease have no FDA-approved therapeutic options. Ocugen is dedicated to providing a gene-agnostic treatment approach for patients living with inherited retinal diseases and is encouraged that the Phase 1/2 GARDian trial for OCU410ST remains on track.

07:01 EDT Tommy Hilfiger, United States SailGP team announce partnership - Tommy Hilfiger, which is part of PVH, announces a multi-year partnership with the United States SailGP Team as Official Lifestyle Apparel Partner of the team. Sharing an ethos of disruption and innovation, Tommy Hilfiger and the US SailGP Team will use the partnership to push the boundaries of performance, design and culture. "Since I was very young, I always loved the world of sailing and the nautical lifestyle - but SailGP is next level; it's a whole new sport," said Tommy Hilfiger. "By fusing intense racing and elite performance with international competition in iconic venues around the world, SailGP is making waves in adrenaline sport. Mike Buckley and the U.S. SailGP team have a unique vision to create a story and an impact that goes well beyond sporting competitions. I am so inspired by their grit, determination and innovation, and together we have the opportunity to disrupt sailing and bring something new to fans globally."

10:56 EDT Bumble and bumble launches in U.S. Amazon Premium Beauty store - Bumble and bumble, an expert hairstyling brand, announces its debut in the U.S. Amazon Premium Beauty store bringing its easy-to-use, high-performing products and styling expertise to new consumers in the U.S. Prime members enjoy fast, free shipping on every order.

06:52 EDT CarMax reports Q1 comparable store used unit sales decreased 3.8% - Retail used unit sales decreased 3.1% and comparable store used unit sales decreased 3.8% from the prior year's first quarter; wholesale units declined 8.3% from the prior year's first quarter, impacted by lower year-over-year seasonal appreciation.

06:32 EDT B2Gold announces sale of C$139M of Calibre Mining shares - B2Gold announces that it has sold an aggregate 79M common shares of Calibre Mining in the ordinary course for investment purposes by way of a block trade for aggregate gross proceeds of C$139.04M. Immediately prior to the Transaction, B2Gold owned 110,950,333 common shares of Calibre representing approximately 14.1% of Calibre. As a result of the Transaction, B2Gold's ownership has decreased to less than 10% of the issued and outstanding common shares of Calibre and B2Gold has ceased to be a "reporting insider" as defined in National Instrument 55-104 - Insider Reporting Requirements. Accordingly, B2Gold will no longer file insider or early warning reports in respect of its ownership of securities of Calibre, except as required by applicable law.

06:13 EDT Texas Instruments, Delta Electronics announce collaboration - Texas Instruments announced a long-term collaboration with Delta Electronics, a global power and energy management manufacturer, to create next-generation electric vehicle onboard charging and power solutions. This work will leverage both companies' research and development capabilities in power management and power delivery in a joint innovation laboratory in Pingzhen, Taiwan. Together, TI and Delta aim to optimize power density, performance and size to accelerate the realization of safer, faster-charging and more affordable EVs.

06:05 EDT CuriosityStream announces new distribution partnership with Harbour Rights - Curiosity Stream is pleased to announce a new distribution partnership with Harbour Rights, an international distribution company based in Hong Kong. This strategic alliance will bring Curiosity Stream's premium content to a broader audience across various platforms, including TV, VOD, and inflight entertainment, in multiple territories across Asia.